ClinicalTrials.Veeva

Menu

Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)

A

Assistance Publique - Hôpitaux de Paris

Status

Unknown

Conditions

Community Aquired Pneumonia

Treatments

Procedure: FOB protected distal microbiological samplings

Study type

Interventional

Funder types

Other

Identifiers

NCT00308659
CNMR grant, cardiff
SCAP FOB

Details and patient eligibility

About

Main hypothesis: microbiological diagnossis off severe community acquired pneumonia can be performed by non invasive or semi invasive microbiological tools, semi invasive tools including protected distal bronchial samplings by the mean of Fiber optic bronchoscopy (FOB). A microbiological diagnosis could improve antibiotic therapy efficacy and improve patient's outcome.

These Two strategies have never been prospectivally evauated.

  • Aim of the study: To evaluate 2 diagnostic strategies: non invasive or semi invasive including protected distal bronchial samplings by the mean of Fiber optic bronchoscopy (FOB)for the care of patients admitted in intensive care for severe community acquired pneumonia and receiving an empirical antibiotic therapy as recommanded by 2001 American thoracic guidelines
  • Type of study randomized multicentric controlled open study

Full description

Type of study randomized multicentric controlled open study

Number of patients: 200 patients (100 patients in each group)admitted in ICU for SCAP

  • Number of center : 5
  • Clinical strategies under evaluation :
  • Group A: semi-invasive strategy: FOB within 24 hours after ICU admission
  • Group B: non-invasive strategy: no FOB within 24 hours after ICU admission
  • Evaluation criteria:

Main criteria: Changes in initial empirical antibiotic treatment according to microbiological results obtained in each group.

others

  • FOB related complications
  • Microbiological results
  • Type of antibiotic treatment modifications
  • ICU outcome and outcome at day 28
  • Duration of antibiotic therapy and nimber of days without antibiotics at day 28 after inclusion

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

New radiological infiltrate SCAP clinical diagnosis admitted in ICU Admitted in hospital for less than 24 hours Aged 18 or older Signed informed consent

Exclusion criteria

Pregnancy Muribond patients Previuos hospitalisation within One month Neutropenia None HIV status

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

HERER BERTRAND, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems